| Schmieder, Roland E |
| Completed | 4 | 105 | Europe | Evolocumab Prefilled Syringe, Placebos | University of Erlangen-Nürnberg Medical School | Atherosclerotic Cardiovascular Disease | 04/21 | 07/21 | | |
NCT06560801: Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation |
|
|
| Recruiting | 4 | 48 | Europe | Dapagliflozin 10mg Tab | University of Erlangen-Nürnberg Medical School | Chronic Kidney Diseases | 10/26 | 12/26 | | |
SEMA, NCT05303857: Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 90 | Europe | Semaglutide Pen Injector, Placebo | University of Erlangen-Nürnberg Medical School | Diabetes Mellitus, Type 2 | 12/23 | 12/24 | | |
| Recruiting | 3 | 75 | Europe | Finerenone 20 MG Oral Tablet, Placebo | University of Erlangen-Nürnberg Medical School, Bayer | Type2diabetes | 06/25 | 12/25 | | |
NCT04321044: Genetic Based Analysis in Hypertensive Patients |
|
|
| Active, not recruiting | N/A | 300 | Europe | Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation | University of Erlangen-Nürnberg Medical School | Hypertension, Renal Denervation, Genetic Predisposition | 07/20 | 12/23 | | |
| Active, not recruiting | N/A | 44 | Europe | Renal denervation | University of Erlangen-Nürnberg Medical School | Uncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease stage3 | 12/23 | 12/23 | | |
NCT06056466: Different Vascular and Renal Parameters in Living Kidney Donors |
|
|
| Completed | N/A | 25 | Europe | | University of Erlangen-Nürnberg Medical School | Renal Injury | 11/23 | 02/24 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT06051812: Proteinuria and Renal Perfusion in Renal Transplant Recipients |
|
|
| Recruiting | N/A | 25 | Europe | | University of Erlangen-Nürnberg Medical School | Pre-kidney Transplant, Living Donor Kidney Transplantation, Renal Perfusion, End Stage Renal Disease | 03/25 | 03/26 | | |
ISTHA, NCT05903586: Vascular Changes in Patients With Aotic Isthmus Stenosis After Interventional Therapy |
|
|
| Recruiting | N/A | 16 | Europe | | University of Erlangen-Nürnberg Medical School | Aortic Isthmus Stenosis | 02/25 | 04/25 | | |
| Active, not recruiting | N/A | 44 | Europe | Renal denervation | University of Erlangen-Nürnberg Medical School | Uncontrolled Hypertension, Autosomal Dominant Polycystic Kidney Disease, Renal Denervation | 03/28 | 03/28 | | |
| Rösler, Wolf |
NCT04291261: Extracorporal Photopheresis with UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease |
|
|
| Completed | 2 | 24 | Europe | Uvadex | Universitätsklinikum Hamburg-Eppendorf, Therakos, University Medical Center Regensburg, Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH | Acute-graft-versus-host Disease | 06/24 | 06/24 | | |
| Fasching, Peter |
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label |
|
|
| Recruiting | 4 | 108 | Europe | Ontruzant, SB3, Chemotherapy, Pertuzumab | Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd. | Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer | 04/23 | 07/23 | | |
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer |
|
|
| Recruiting | 4 | 82 | Europe | Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel | Institut fuer Frauengesundheit, Eisai GmbH | Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic | 07/23 | 09/23 | | |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency ( |
|
|
| Active, not recruiting | 2 | 11 | Europe | Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza | Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC | Malignant Neoplasm of Breast, Breast Cancer | 01/25 | 02/26 | | |
| Recruiting | 2 | 240 | Europe | Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, Inavolisib, Ipatasertib, Olaparib, Lynparza, Sacituzumab govitecan, Trodelvy, Trastuzumab/pertuzumab, Phesgo | German Cancer Research Center | Early-stage Breast Cancer | 03/30 | 12/30 | | |
| Completed | 1/2 | 186 | Europe, US, RoW | ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Triple Negative Breast Neoplasms | 09/24 | 09/24 | | |
| Recruiting | 1/2 | 68 | Europe, US, RoW | Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio | Stemline Therapeutics, Inc., Stemline Therapeutics, Inc | Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases | 12/25 | 12/25 | | |
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 124 | Europe, US, RoW | MEN2312, Elacestrant | Stemline Therapeutics, Inc. | Advanced Breast Cancer | 10/25 | 10/26 | | |
| Recruiting | N/A | 3000 | Europe | | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma | 12/23 | 12/23 | | |
PRO2, NCT05425550: Evaluation of the Medidux™ Digital Health Application in Patients with HER2-positive Breast Cancer During Chemotherapy in Combination with HER2-targeted Therapy or Antibody-drug Conjugate Therapy. |
|
|
| Recruiting | N/A | 585 | Europe | medidux™ app | Palleos Healthcare GmbH, Mobile Health AG | Breast Cancer | 09/25 | 09/25 | | |
| Recruiting | N/A | 13500 | Europe | Blood sampling | University Hospital Tuebingen | Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer) | 03/26 | 03/27 | | |
| Recruiting | N/A | 2000 | Europe | Genomic Profiling / Sequencing | German Cancer Research Center, University Hospital Heidelberg, German Federal Ministry of Education and Research | Early-Stage Breast Cancer, Neoadjuvant Therapy | 12/28 | 12/28 | | |
NCT04755829: Breath Test to Predict Breast Cancer and Outcome of Mammography |
|
|
| Not yet recruiting | N/A | 1000 | Europe | BreathX test for breath VOCs | Menssana Research, Inc., Mount Vernon Cancer Centre, Zuyderland Medical Centre, University of Erlangen-Nürnberg | Breast Cancer, Abnormal Mammogram, Unspecified | 03/23 | 03/23 | | |
CATCH, NCT05652569: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 5000 | Europe | Genomic Profiling / Sequencing | German Cancer Research Center, University Hospital Heidelberg | Metastatic Breast Cancer | 12/30 | 12/30 | | |
| Ferstl, Barbara |
| Recruiting | 1/2 | 48 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory | 12/24 | 12/24 | | |
